Regulatory macrophage secretory products

1 paper6 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Cells1

Outcomes

6

Activin A

downin human cells1

1 study

Regulatory macrophage secretory products decrease activin A in human cells.
“In HUVEClp SPMreg increased β-galactosidase activity, attenuated the time-dependent increase of ROS levels and secretion of SASP factor Activin A (P < 0.05 for all).”
CellsLate passage cells, passages 10–13; secretion readouthuman umbilical vein endothelial cells10 days
Secretory products from regulatory macrophages modulate senescence in human endothelial cells: implications for cardiovascular aging and diseases
BMC cardiovascular disorders31 Mar 2026

More on Activin A

PAI-1

downin human cells1

1 study

Regulatory macrophage secretory products decrease PAI-1 in human cells.
“In HUVECep, SPMreg increased β-galactosidase activity and the proportion of ROS-positive cells, while reducing secretion of the SASP factor PAI-1 (P < 0.05 for all).”
CellsEarly passage cells, passages 4–6; secretion readouthuman umbilical vein endothelial cells10 days
Secretory products from regulatory macrophages modulate senescence in human endothelial cells: implications for cardiovascular aging and diseases
BMC cardiovascular disorders31 Mar 2026

Reactive oxygen species

downin human cells1

1 study

Regulatory macrophage secretory products decrease reactive oxygen species in human cells.
“In HUVEClp SPMreg increased β-galactosidase activity, attenuated the time-dependent increase of ROS levels and secretion of SASP factor Activin A (P < 0.05 for all).”
CellsLate passage cells, passages 10–13; attenuation of the time-dependent increasehuman umbilical vein endothelial cells10 days
Secretory products from regulatory macrophages modulate senescence in human endothelial cells: implications for cardiovascular aging and diseases
BMC cardiovascular disorders31 Mar 2026

More on Reactive oxygen species

ROS-positive cells

upin human cells1

1 study

Regulatory macrophage secretory products increase ROS-positive cells in human cells.
“In HUVECep, SPMreg increased β-galactosidase activity and the proportion of ROS-positive cells, while reducing secretion of the SASP factor PAI-1 (P < 0.05 for all).”
CellsEarly passage cells, passages 4–6human umbilical vein endothelial cells10 days
Secretory products from regulatory macrophages modulate senescence in human endothelial cells: implications for cardiovascular aging and diseases
BMC cardiovascular disorders31 Mar 2026

More on ROS-positive cells

Beta-galactosidase

upin human cells1

1 study

Regulatory macrophage secretory products increase beta-galactosidase in human cells.
“In HUVEClp SPMreg increased β-galactosidase activity, attenuated the time-dependent increase of ROS levels and secretion of SASP factor Activin A (P < 0.05 for all).”
CellsLate passage cells, passages 10–13; activity readouthuman umbilical vein endothelial cells10 days
Secretory products from regulatory macrophages modulate senescence in human endothelial cells: implications for cardiovascular aging and diseases
BMC cardiovascular disorders31 Mar 2026

More on Beta-galactosidase

Cell size and volume

downin human cells1

1 study

Regulatory macrophage secretory products decrease cell size and volume in human cells.
“In HUVEClp, treatment with SPMreg significantly reduced cell size and volume at all time points (P < 0.05).”
CellsLate passage cells, passages 10–13human umbilical vein endothelial cells10 days
Secretory products from regulatory macrophages modulate senescence in human endothelial cells: implications for cardiovascular aging and diseases
BMC cardiovascular disorders31 Mar 2026

Latest

1 in 12 months

BMC Cardiovascular Disorders31 Mar

Secretory products from regulatory macrophages modulate senescence in human endothelial cells: implications for cardiovascular aging and diseases

Experiments in human cellsInterventions